APG Asset Management N.V. Has $169,981,000 Stake in Bristol-Myers Squibb Co. (BMY)
APG Asset Management N.V. boosted its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 10.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,152,466 shares of the biopharmaceutical company’s stock after buying an additional 290,100 shares during the period. APG Asset Management N.V. owned about 0.19% of Bristol-Myers Squibb worth $169,981,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in BMY. Stockman Asset Management raised its position in shares of Bristol-Myers Squibb by 144.7% in the third quarter. Stockman Asset Management now owns 35,425 shares of the biopharmaceutical company’s stock valued at $1,910,000 after buying an additional 20,950 shares in the last quarter. Jensen Investment Management Inc. raised its position in Bristol-Myers Squibb by 0.9% in the third quarter. Jensen Investment Management Inc. now owns 33,300 shares of the biopharmaceutical company’s stock valued at $1,796,000 after buying an additional 300 shares during the period. Vicus Capital raised its position in Bristol-Myers Squibb by 25.9% in the third quarter. Vicus Capital now owns 7,582 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 1,558 shares during the period. Wedgewood Investors Inc. PA raised its position in Bristol-Myers Squibb by 4.8% in the third quarter. Wedgewood Investors Inc. PA now owns 4,367 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 200 shares during the period. Finally, Mathes Company Inc. raised its position in Bristol-Myers Squibb by 15.2% in the third quarter. Mathes Company Inc. now owns 5,302 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 700 shares during the period. 68.84% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Co. (NYSE:BMY) opened at 56.36 on Wednesday. Bristol-Myers Squibb Co. has a 12 month low of $49.03 and a 12 month high of $77.12. The company’s 50-day moving average is $52.72 and its 200-day moving average is $62.87. The stock has a market capitalization of $94.19 billion, a P/E ratio of 28.19 and a beta of 0.90.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.12. Bristol-Myers Squibb had a net margin of 18.54% and a return on equity of 28.98%. The firm had revenue of $4.83 billion for the quarter, compared to analyst estimates of $4.76 billion. During the same quarter in the prior year, the firm earned $0.39 EPS. The company’s revenue was up 21.0% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current year.
BMY has been the subject of several research reports. Credit Suisse Group AG lowered shares of Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $86.00 to $63.00 in a report on Sunday, August 7th. Leerink Swann reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Bristol-Myers Squibb in a report on Sunday, October 9th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a report on Thursday, August 25th. Jefferies Group reaffirmed a “hold” rating and issued a $57.00 price target (down from $69.00) on shares of Bristol-Myers Squibb in a report on Monday, September 12th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $75.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, September 27th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $67.51.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares in the company, valued at approximately $19,022,958.13. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.24% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.